Skip to main content

Company Comparison

Veracyte vs 23andMe

Side-by-side comparison of two portfolio companies — sector, funding stage, investors, valuation, and more.

MetricVeracyte23andMe
SectorBiotechBiotech
HeadquartersSouth San Francisco, CASouth San Francisco, California
Founded20082006
StatusActiveActive
Last Funding StageIPO
Total Funding$142M
Valuation

What They Build

Veracyte

Genomic diagnostics company that develops molecular tests to help physicians make treatment decisions for patients with thyroid, lung, and breast diseases.

23andMe

23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California.

Key Investors

Sector Overlap

Both Veracyte and 23andMe operate in Biotech.

Browse all Biotech companies →

Websites

Sponsored
AArchstone

The operating system for private capital.

Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.

LP portal & reportingCapital callsPortfolio tracking$297/moNo AUM fees

Now in alpha with select funds. 14-day trial available.